emerging ibrutinib-based combinations in cll
Published 2 years ago • 72 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
2:18
the combination of ibrutinib and obinutuzumab in cll
-
2:45
optimizing the combination of ibrutinib plus venetoclax in cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
1:09
ibrutinib combination therapy in cll: overview of the data so far
-
2:00
ibrutinib: use in small cll subgroups only?
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
7:13
using ibrutinib in chronic lymphocytic leukemia (cll)
-
6:48
patient selection for treatment with ibrutinib in cll
-
1:01
selinexor for cll - mechanism of action and combination with ibrutinib
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
1:32
novel agent combinations: the future of cll
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
1:46
novel agent combinations for cll: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
-
5:52
understanding ultra high-risk cll and advances with ibrutinib therapy
-
2:51
genetic markers in patients with early-stage cll treated with ibrutinib: findings from cll12
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
2:06
effects of dose adjustment of first-line ibrutinib on real-world dosing patterns and outcomes in cll
-
2:14
ibrutinib's role in cll treatment and future outlooks
-
2:41
small molecule-chemotherapy combinations: ibrutinib plus rituximab for cll
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
3:46
the characteristics and mode of action of ibrutinib for cll